News

A recent study published in the journal Nature, studied the potential of using ketamine to treat patients with borderline personality disorder (BPD). In a pilot randomized controlled trial, scientists investigated the effect of a single dose of ketamine on the emotional state of patients.

Borderline personality disorder is a complex mental disorder characterized by significant emotional instability, impulsive behavior, a tendency to self-harm, and difficulties in relationships. Traditional treatments for BPD include therapy, antidepressants, and mood stabilizers, but these approaches often take a long time to achieve significant effects.

In mid-June of this year, the director of the Expio center Wladyslaw Matrenytskyi took part in an international seminar in Warsaw, which was organized by the European Alliance for Psychedelic Access and Research (PAREA) in cooperation with the Open Society Foundation, the International Renaissance Foundation, the Helsinki Human Rights Foundation and the Ukrainian Association psychedelic research.

The main goal of the workshop was to develop a common situational understanding and program
advocacy, as well as providing tools and expertise to support Ukraine in expanding access
to psychedelic therapy for people with post-traumatic stress disorder associated with
by war

United 24 TV channel presents report about our clinic and ketamine therapy. Translation by specialists of our clinic.

Now there is a lot of talk about the reconstruction of Ukraine, and most of the talk is about infrastructure, inanimate objects that can be destroyed to make way for something new. However, there is an underestimated human element of recovery that has a much more complex road map to recovery.

"I got 5 concussions. The last one was very serious," Oleg Kazantsev, a former junior sergeant of the Armed Forces of Ukraine, tells me while we are sitting in a clinic in Kyiv. "After recovering in the hospital, I returned home and that's when the changes began. PTSD started. I didn't want to leave my house."

According to the Centers for Disease Control and Prevention (CDC), depression alone causes 200 million lost work days each year, costing employers more than $44 billion.

Dr. Bonners, CEO of Magic Soap, saw the depth of mental health problems many workers faced during the pandemic, so he turned his attention to the drug ketamine, which is currently used to treat depression and anxiety.

At the beginning of June this year, the director of the Expio center, Vladyslav Matrenytskyi, took part in an international seminar on ketamine-assisted therapy in Barcelona (Spain), which was jointly organized by the "Sinaptica" clinic (Barcelona), the Dr. Scheib Institute (Mallorca) and the Ketamine Research Foundation (KRF). , USA).

During the comprehensive 5-day program, participants delved into the theory and practice of psychedelic ketamine therapy and gained the knowledge and skills necessary for confident independent use of these treatment methods.

During the seminar, Vladyslav Matrenytskyi spoke to the participants about the peculiarities of the use of ketamine therapy during the war in Ukraine.

TV channel Arte (Germany) made a report about the mental trauma of war and its overcoming, including with the help of psychedelic therapy in our clinic.

"After almost two years of war, Ukraine is a traumatized nation. A significant part of the population suffers from physical or psychological injuries, and often from both. Tracks East looks at how the country is dealing with mass trauma.”

https://www.arte.tv/en/videos/117217-003-A/tracks-east/

Psychedelics can help them overcome their trauma and possibly fight back

Ihor Kholodylo was probably not supposed to survive. A military psychologist and medic was evacuating his comrades in early 2023 when his jeep was hit by a Russian tank shell. He remained barely able to communicate. The operation saved his heart and eyesight. But doctors were unable to correct his speech problem and stuttering. He tried all kinds of radical therapy, but nothing helped. Then he met Vladyslav Matrenytskyi, a pioneer of psychedelic psychotherapy, who asked an unexpected question. Would he try ketamine?

Last week, Congress approved a defense spending bill that will fund military research and clinical trials of cannabis, psilocybin and other psychedelic drugs to determine their effectiveness in treating service members and veterans with post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Adoption of section 723 Law on Authorization for National Defense (NDAA) would allow members of the military to undergo psychedelic therapy and provide $10 million to explore this option as a new approach to mental health treatment.

Details about the new draft law

Back in June, the Senate Appropriations Committee proposed military spending bill , which contains several requests for the 2024 military construction budget. Among these requests was an important directive to expand research into the therapeutic benefits of psychedelics. The committee urged the Department of Veterans Affairs (VA) to investigate the potential of these substances to treat various health conditions common among veterans, such as post-traumatic stress disorder, major depressive disorder, and chronic pain. This directive was a crucial component of a broader approach to treating veterans' mental health through psychedelic therapy.